Literature DB >> 25211359

Intraoperative corneal thickness monitoring during corneal collagen cross-linking with isotonic riboflavin solution with and without dextran.

Refik Oltulu1, Günhal Şatirtav, Meryem Donbaloğlu, Hürkan Kerimoğlu, Ahmet Özkağnici, Adnan Karaibrahimoğlu.   

Abstract

PURPOSE: The aim of this study was to analyze and compare corneal thickness changes during corneal collagen cross-linking procedures performed with isoosmolar riboflavin solution with 20% dextran and without dextran in corneal ectatic diseases.
METHODS: The patients in this study were analyzed in 2 groups: group 1 receiving riboflavin solution containing 20% dextran and group 2 receiving dextran-free riboflavin solution. Corneal thickness measurements were obtained with ultrasonic pachymetry at 6 different time points: preoperatively and at 0, 15, 30, 45, and 60 minutes after epithelial removal and initiation of ultraviolet A irradiation.
RESULTS: Twenty-seven eyes of 27 patients with progressive keratoconus were included in the study. In group 1 (n = 13), the mean preoperative thinnest pachymetric readings were 469.3 ± 8.5 μm, which decreased to 423.8 ± 8.9 μm after deepithelization and further decreased to 385.9 ± 10.9 μm at 15 minutes. The corneal thickness assumed a steady course at the 30-, 45-, and 60-minute measurements (378.9 ± 9.8 μm, 384.5 ± 10.5 μm, and 396.7 ± 9.4 μm, respectively). The initial change was statistically significant (P < 0.01). In group 2 (n = 14), the corneal thickness decreased from 459.4 ± 3.8 μm to 414.7 ± 2.6 μm with deepithelization, after which it increased steadily with the initiation of the dextran-free riboflavin solution. The final measurement in group 2 was 474.1 ± 9.4 μm; the increase at each time point was statistically significant when compared with the previous measurement (P < 0.01).
CONCLUSIONS: Using isoosmolar riboflavin solution without dextran causes a steady increase in the corneal thickness during the cross-linking procedure, as opposed to riboflavin with dextran. This result might be beneficial in broadening the spectrum of cross-linking indications in patients with thin corneas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25211359     DOI: 10.1097/ICO.0000000000000249

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  6 in total

1.  Standard, transepithelial and iontophoresis corneal cross-linking: clinical analysis of three surgical techniques.

Authors:  Settimio Rossi; Carmine Santamaria; Rosa Boccia; Luigi De Rosa; Francesco Maria D'Alterio; Francesca Simonelli; Giuseppe De Rosa
Journal:  Int Ophthalmol       Date:  2017-11-28       Impact factor: 2.031

2.  Intraoperative optical coherence tomography to evaluate the effect of the eyelid speculum on corneal pachymetry during accelerated corneal cross-linking (9 mW/cm2).

Authors:  R Ghaffari; M Mortazavi; P Anvari; A Salamat Rad; F Alipour; F Hafezi; S Asgari; H Hashemi
Journal:  Eye (Lond)       Date:  2017-11-24       Impact factor: 3.775

3.  The Intraoperative Corneal Pachymetry Changes during Accelerated Corneal Cross-linking in Progressive Keratoconus Patients with Thin Corneas.

Authors:  Serap Yurttaşer Ocak; Mehmet Serhat Mangan; Mustafa Nuri Elçioğlu
Journal:  Korean J Ophthalmol       Date:  2021-09-06

Review 4.  Pediatric Crosslinking: Current Protocols and Approach.

Authors:  Júlia Polido; Maria Emília Dos Xavier Santos Araújo; João G Alexander; Thiago Cabral; Renato Ambrósio; Denise Freitas
Journal:  Ophthalmol Ther       Date:  2022-04-28

5.  One-year outcomes of conventional and accelerated collagen crosslinking in progressive keratoconus.

Authors:  Vanissa W S Chow; Tommy C Y Chan; Marco Yu; Victoria W Y Wong; Vishal Jhanji
Journal:  Sci Rep       Date:  2015-09-25       Impact factor: 4.379

6.  Intraoperative Corneal Thickness Changes during Pulsed Accelerated Corneal Cross-Linking Using Isotonic Riboflavin with HPMC.

Authors:  Ahmed M Sherif; Nihal A El-Gheriany; Yehia M Salah El-Din; Lamiaa S Aly; Amr A Osman; Michael A Grentzelos; George D Kymionis
Journal:  J Ophthalmol       Date:  2016-01-13       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.